Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Neurotrophic Keratitis > Shelf-stable amniotic membrane shows short- and long-term improvements in ocular surface disease
  • Neurotrophic Keratitis

Shelf-stable amniotic membrane shows short- and long-term improvements in ocular surface disease

Ophthalmology 360

Key Takeaways

  1. Most eyes showed improved corneal staining and symptoms within about 4 days of CAM placement.
  2. Improvements were maintained at approximately 16 weeks in many eyes.
  3. No serious complications were reported, with only mild irritation in a few cases.

Adjunctive use of shelf-stable, cryopreserved amniotic membrane (CAM) was associated with improvements in corneal staining and symptoms within days, with benefits maintained for several months in many patients with ocular surface disease (OSD), according to a retrospective study.

The analysis included 20 consecutive patients (29 eyes) treated using shelf-stable CAM placed with a 72-hour collagen shield or bandage contact lens, followed by partial tape tarsorrhaphy. Patients had dry eye disease (14 eyes), neurotrophic keratopathy (5 eyes), or superficial punctate keratitis (10 eyes). Outcomes assessed at approximately one week and at last follow-up (12–24 weeks) included corneal staining, symptoms, visual acuity, and corneal sensitivity.

Mean corneal staining scores improved from 2.26 ± 1.07 to 1.00 ± 0.91 (P < 0.001), with 84.6% of eyes showing improvement approximately 4 days after CAM placement. Symptomatic improvement, defined as resolution of at least 1 pre-treatment symptom, was observed in 92.3% of eyes at this early follow-up.

At longer-term follow-up, occurring at approximately 16 weeks, corneal staining scores remained improved at 1.55 ± 1.13 (P = 0.014). Trace or complete resolution of staining was observed in 25% of eyes, while 60% demonstrated improvement. Symptomatic improvement was reported in 65% of eyes at long-term follow-up.

No serious complications were reported. Two cases of irritation were associated with collagen shield use, and one case of outer eyelid irritation was attributed to adhesive tape.

Reference
Cushman S. Shelf-Stable, Cryopreserved Amniotic Membrane for the Management of Ocular Surface Disease: A Retrospective Assessment. Clin Optom (Auckl). 2025;17:409-415. doi: 10.2147/OPTO.S563708. PMID: 41459351; PMCID: PMC12739937.

Share

Related Content

  • Ocular Surface Disease

Scleral lenses improve vision and symptoms across ocular surface diseases

  • Neurotrophic Keratitis

Shelf-stable amniotic membrane improved outcomes in early-stage neurotrophic keratopathy

  • Dry Eye

Spotlight on LACRIFILL®

  • Conference Roundup

Cryopreserved amniotic membrane significantly improves ocular surface integrity in patients with severe keratoconjunctivitis sicca and neurotrophic keratopathy

  • Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

  • Conference Roundup

If your patient has recurrent chalazia, consider co-occurring Demodex blepharitis

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon